NMS Capital has exited its investment in Flourish Research, a US-based clinical trial organization, through a sale to Genstar Capital. No financial terms were disclosed.

Original research ranges from new concepts in human biology and disease pathogenesis to new therapeutic modalities and drug development, to all phases of clinical work, as well as innovative ...

BioDuro-Sundia opens new kilogram laboratory at Shanghai to speed development from discovery to preclincal and clinical ...

TD Cowen analyst Tyler Van Buren maintained a Buy rating on EyePoint Pharmaceuticals (EYPT – Research Report ... based on EyePoint Pharmaceuticals’ notable advancements in their clinical trials and ...

biomodal, an omics-based life sciences technology and analytics company, today announced it will present new data highlighting the utility of duet mul ...

Wireless Polysomnography MarketThe global wireless polysomnography (PSG) market, valued at USD 197.7 million in 2023, is projected to reach USD 329.8 million by 2033, growing at a CAGR of 5.2% during ...

For instance, AI algorithms can rapidly screen millions of compounds, significantly speeding up the initial phases of drug ..

Innovative products, such as those being developed by DELFI, will aid in the efficient progress of those medicines through the clinic," said Susan Macdonald, PhD, SVP Nonclinical Development & ...